ArticleFrontiers in oncology2025
Prognostic value of LODDS in late-onset gastric adenocarcinoma: analysis of SEER, TCGA, and external multicenter cohorts.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A nomogram integrating multidimensional lymph node indicators with clinicopathological factors predicts overall survival in non-metastatic gastric cancer patients after radical gastrectomy.Translational cancer research · 2026Article
- Adjuvant chemotherapy and lymph node examination interact to shape survival in older adults (≥ 75 years) with resected gastric cancer: a SEER-based propensity score-matched and competing-risk analysis.World journal of surgical oncology · 2026Article
- Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer.Journal of gastrointestinal oncology · 2026Article
- Optimizing gastric cancer treatment: the role of LODDs in lymph node staging.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate survival prediction is crucial for optimizing individualized treatment and follow-up in patients with late-onset gastric adenocarcinoma (LOGA). Traditional lymph node staging systems such as N-stage, positive lymph node (PLN), and lymph node ratio (LNR) have limitations in predictive accuracy, especially in cases with inadequate lymph node dissection. The log odds of positive lymph nodes (LODDS), a novel nodal staging metric that incorporates both positive and negative lymph nodes through a log-transformed ratio, has shown potential advantages by providing a more stable and refined assessment of nodal involvement. Materials and methods: This study included 10,361 LOGA patients from the SEER database, 135 from TCGA, and 252 from two medical centers. A novel prognostic model was constructed based on a training cohort from SEER and validated using internal (SEER testing set) and external (TCGA and hospital datasets) cohorts. The model incorporated age, gender, grade, size, chemotherapy, and LODDS. Four staging systems (TNM-stage, PLN-stage, LNR-stage, LODDS-stage) were compared using the Akaike Information Criterion (AIC), Concordance Index (C-index) and time-dependent Area Under the Curve (AUC). LODDS-stage model, the most effective model, was used to build nomograms for overall survival (OS) and cause-specific survival (CSS). Model performance was evaluated using calibration curves, Decision Curve Analysis (DCA), and Kaplan-Meier analysis. Results: Univariate and multivariate Cox regression identified age, gender, grade, tumor size, chemotherapy, and LODDS-stage as independent prognostic factors. Among the four models, the LODDS-based model showed the highest discrimination and best calibration for predicting OS and CSS at 1, 3, 5, and 10 years. Nomograms incorporating these variables exhibited excellent predictive accuracy in both internal and external cohorts. Survival risk classification based on model scores effectively stratified patients into high- and low-risk groups, with significantly different survival outcomes across all datasets (p < 0.05). Conclusions: The LODDS-based prognostic model outperformed traditional nodal staging systems in survival prediction for LOGA patients. This model showed high accuracy and consistent performance across different datasets, indicating its potential to support personalized treatment and long-term follow-up strategies for elderly patients with gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.